Switch to Biosimilar Inflectra from Remicade Supported by Report at 2016 UEG Week

Switch to Biosimilar Inflectra from Remicade Supported by Report at 2016 UEG Week
Phase 4 trial results were recently presented that supported switching patients from Remicade (infliximab) to its biosimilar drug Inflectra as a safe and non-inferior alternative. The results, presented at the UEG (United European Gasroenterology) Week 2016 in Vienna, Austria, came from the NOR-SWITCH study in adult patients who had been switched to Inflectra treatment for 52 weeks for many conditions. NOR-SWITCH (NCT02148640) was a randomized, double-blind,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *